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Abstract: Among nature’s arsenal of oxidative enzymes, cytochrome P450s (CYPs) catalyze the most
challenging reactions, the hydroxylations of non-activated C  H bonds. Human CYPs are studied in drug
development due to their physiological role at the forefront of metabolic detoxification, but their challenging
handling makes them unsuitable for application. CYPs have a great potential for biocatalysis, but often lack
appropriate features such as high and soluble expression, self-sufficient internal electron transport, high
stability, and an engineerable substrate scope. We have probed these characteristics for a recently described
CYP that originates from the thermophilic fungus Thermothelomyces thermophila (CYP505A30), a homolog
of the well-known P450-BM3 from Bacillus megaterium. CYP505A30 is a natural monooxygenase-reductase
fusion, is well expressed, and moderately tolerant towards temperature and solvent exposure. Although overall
comparable, we found the stability of the enzyme’s domains to be inverse to P450-BM3, with a more stable
reductase compared to the heme domain. After analysis of a homology model, we created mutants of the
enzyme based on literature data for P450-BM3. We then probed the enzyme variants in bioconversions using a
panel of active pharmaceutical ingredients, and activities were detected for a number of structurally diverse
compounds. Ibuprofen was biooxidized in a preparative scale whole cell bioconversion to 1-, 2- and 3-
hydroxyibuprofen.
Keywords: active pharmaceutical ingredient; biocatalysis; heme proteins; hydroxylation; ibuprofen; oxygenation;
self-sufficient cytochrome P450
Introduction
One of the most challenging reactions in organic
chemistry is the oxidation of non-activated carbons.
Overcoming the inertness of C  C and C  H bonds
requires very high reaction temperatures or highly
reactive chemical species, commonly resulting in
energy intensive and poorly controllable processes.[1]
In nature, ubiquitously found enzymes called cyto-
chrome P450s (CYPs or P450s) use molecular oxygen
as the oxidant to perform various oxidation reactions
(hydroxylations, dealkylations, heteroatom oxidations
and epoxidations), while forming water as the
byproduct.[2] Initially, CYPs were studied in humans:
acting as a phase I metabolic frontier, P450s oxidize
xenobiotics to increase their solubility and activate
them for further metabolism.[3] With the majority of
drugs being direct substrates, the comprehension of
CYPs is of paramount importance in clinical and
pharmaceutical science. However, the physiologically
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obligatory substrate promiscuity rendered them also as
valuable biocatalysts for the selective oxidation of
non-activated carbons under mild process conditions.[4]
The complex reaction mechanism (Scheme 1) en-
abling the remarkable chemistry of P450s involves a
heme prosthetic group, whose porphyrin ring coordi-
nates an iron atom that is proximally ligated to a
cysteine. If a suitable substrate enters the active site, it
displaces an axial water molecule and triggers the
reductive activation of oxygen. Electrons from a
nicotinamide cofactor (NADPH or NADH) are succes-
sively shuttled through a reductase system to the heme.
The one electron-reduced ferrous state binds dioxygen
and the second electron creates the ferric peroxy
complex. Protonation and water elimination yields
“Compound I”, which reacts with the substrate through
a radical-rebound mechanism.[2]
Unproductive pathways shortcutting this principle
cycle lead to the uncoupling of electron consumption
from product formation and can create hydrogen
peroxide (H2O2) or superoxide. This characteristic can
be exploited to drive the reaction reverse using excess
H2O2, leading to a cofactor-avoiding shunt pathway.
[7]
In nature, most often an FAD-containing reductase acts
as the hydride acceptor, and a ferredoxin or flavodoxin
as the single electron mediator. The individual
components can exist as separate, or as fused, multi-
domain proteins (“self-sufficient”). The various possi-
ble combinations differentiate the CYP subclasses. In
bacteria, the CYP system is typically cytosolic, while
it is membrane-bound in eukaryotes.[6] For this reason,
the physiologically relevant human CYPs, which are
membrane-bound two component systems, are typi-
cally isolated in microsomes and their handling is
generally challenging.[8] An easier to study model
system was found in CYP102A1 (also known as P450-
BM3) from Bacillus megaterium. P450-BM3 is solu-
ble, all components are fused to one polypeptide, and
the single electron mediator is an FMN-containing,
flavodoxin-like domain, equivalent to the human
microsomal system.[9] Significant advances in under-
standing CYP’s redox transfer mechanisms were made
with P450-BM3,[5b] but due to its unprecedented
catalytic rate, it was quickly conceived as an out-
Scheme 1. Catalytic cycle of cytochrome P450s[5] (CYPs) and comparison of membrane-bound Class II (depicted in the first
electron transfer step) and soluble class VIII CYPs (depicted for the second electron transfer step).[6] In both classes, the two
required electrons originate from a hydride transferred from NAD(P)H. The electron acceptor is a flavin cofactor in a cytochrome
P450 reductase, which is either a separate enzyme (class II) or a fused domain (class VIII). The electrons are successively shuttled
to the heme via a second flavin, allowing first the reaction with dioxygen and then the maturation to the catalytically active
“compound I” (marked by *). Uncoupling pathways (grey dashed lines) can lead to the formation of reactive oxygen species.
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standing biocatalyst as well.[10] After the crystal
structure was solved,[11] this notion has since been
corroborated by the accomplishments in engineering
the enzyme to work on countless unnatural substrates.
Desired activities are generally either of interest for
organic synthesis, e. g. in late stage func-
tionalization,[12] or mimic human drug metabolism. The
latter can substantially simplify pharmacokinetic stud-
ies, where an access to drug metabolites is required for
adverse drug reaction assessments or prodrug
studies.[13]
Since many target compounds for P450s are hydro-
phobic, organic solvent systems commonly need to be
applied. In this regard, (industrial) application of CYPs
encountered a major hurdle, because they typically
suffer from poor stability in these conditions.[14] Be-
sides the use of solvents, industrial processes often run
optimally at elevated temperatures to increase reaction
rates and compound solubility. Thermo- and solvent
stability of proteins often go hand in hand and can be
improved simultaneously.[15] Although the mesophilic
P450-BM3 is already considerably more stable than
e.g. human CYPs,[16] it was engineered toward even
higher solvent- and thermostability using random
mutagenesis.[17] However, considerable improvements
need to be achieved for application of a P450
biocatalyst in most industrial processes.[18]
Here we report on our investigations on a recently
characterized CYP from the fungus Thermothelomyces
thermophila (CYP505A30).[19] This enzyme is of the
same class as P450-BM3 and could emerge as an
alternative biocatalyst due to its mesophilic nature and
distinct substrate scope. We show that CYP505A30’s
stability is similar to P450-BM3’s, but with inverted
stability differences between the P450 and reductase
domains. Further characterization of the enzyme was
conducted and several substrates for the wild-type and
mutated variants were identified.
Results and Discussion
Stimulated by our previous experience in identifying
biocatalytically interesting oxidoreductases in the ther-
mophilic fungus Thermothelomyces thermophila[20] (for-
merly known as Myceliophthora thermophila[21]) we
decided to focus on a gene encoding a cytochrome
P450-homolog (locus tag MYCTH_101224). Sequence
alignment revealed the gene to consist of a single open
reading frame for a self-sufficient P450 of 1080 amino
acids, identical to CYP505A30.[19] A synthetic and
codon-optimized gene was cloned in a pET28a vector
conferring an N-terminal 6x histidine tag, and the
protein was expressed in Escherichia coli BL21 (DE3).
Nickel-Sepharose affinity chromatography yielded a
protein of approximately 125 kDa, as estimated by
SDS-PAGE (Figure S1). The red-brown protein showed
a major absorption peak at 415 nm. Upon reduction and
carbon monoxide binding, the characteristic 450 nm
soret band was observed. Dodecanoic (lauric) acid was
used as a standard substrate. Fast consumption of either
NADH or NADPH was observed when followed
spectrophotometrically at 340 nm in the presence of
1 μM of enzyme and 1 mM substrate, confirming a
catalytically competent and self-sufficient monooxyge-
nase with preference for NADPH, in agreement with
what was reported recently.[19] In the absence of an
organic substrate, we measured an NADPH oxidation
“leak rate” of only 0.02 s  1, significantly lower than the
reported values for P450-BM3, which range from
0.083 s  1 to 0.5 s  1.[22] GC-MS analysis of the ethyl
acetate-extracted and TMS-derivatized reaction mix
containing a phosphite dehydrogenase-based NADPH
regeneration system[23] confirmed a hydroxylating activ-
ity on lauric acid. We found full conversion after 24 h
and 86% ω-1 oxidation (Figure S2). A similar result
was reported by Baker et al.[19]
We next assessed the thermostability of
CYP505A30 under varying conditions by determining
its apparent melting temperature (Tm). Using a thermal-
shift assay, the unfolding of the entire protein can be
monitored by supplementing a dye that exhibits
fluorescence upon binding to the exposed hydrophobic
core. The Tm is defined as the temperature at the
inflection point of the corresponding melting curve.
For CYP505A30, we observed two distinct melting
temperatures that differed by approximately 8 °C,
attributable to a three-state unfolding. Using princi-
pally the same assay, Baker et al. did not observe such
an apparent intermediate state, which may be due to
the different protocol in temperature ramping. The two
Tms are in good agreement, however, for what they
reported as the unfolding temperature of the full
protein (58 °C) and a truncated protein consisting of
only the heme domain (48 °C), respectively. To
establish whether the second maximum corresponds to
the reductase domain, we performed the same assay
without addition of dye, following the fluorescence of
the flavin cofactors instead. As expected, this so-called
ThermoFAD method[24] resulted in only one peak for
the Tm, which we assigned to the flavin-containing
reductase domain (Figure S3). In contrast to P450-
BM3, CYP505A30 showed a higher stability for the
reductase domain as compared to the heme domain.
Figure 1A shows the pH-dependent melting temper-
atures of the two domains of CYP505A30 in a pH
range from 3.6–9. The protein displayed a maximal
stability at slightly acidic pH, with the maximum Tm of
the reductase domain found to be 56.3 °C at pH 6, and
the highest Tm of the heme domain of 49.8 °C at
pH 5.6. Although Baker et al. reported a stability
maximum at pH 7, Figure 1A shows that CYP505A30
displays a very broad pH stability and a barely changed
Tm of the reductase domain in the pH range 5–7.5. This
stability is an attractive feature from an application
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point of view and one that also facilitates kinetic
studies and the investigation of protonation states in
the electron transfer reactions. When comparing the
Tms to literature data, we found them to be similar to
P450-BM3, which showed three distinct peaks of 48 °
C, 58.4 °C and 63 °C in a differential scanning
calorimetry assay.[16] In the case of P450-BM3,
however, the reductase domain corresponds to the
lowest unfolding temperature. With the distinct (poten-
tially irreversible) unfolding event at 58.4 °C likely
being deleterious to the heme domain’s activity,
CYP505A30 and P450-BM3 basically inactivate at the
same temperatures, although with an inversion of the
unfolding order of the domains. Because stability is
not necessarily correlated to catalytic activity, we also
determined a pH profile of apparent activity by
measuring NADPH consumption in the same pH range
as before (Figure 1B). The pH range of oxidation
activity was found to be more narrow and similar to
what was described for P450-BM3.[25] In contrast to
the stability optimum, the enzyme was found to
oxidize the cofactor fastest at pH 7.4, about 1.5 pH
units above the stability optimum.
To further assess the stability and applicability of
CYP505A30, we also measured the Tm and NADPH
consumption in the presence of various cosolvents.
With increasing solvent levels, we found an approx-
imately linear decrease of stability. The effect was
relatively limited and depended on the type of solvent.
The strongest effect was measured with 10% ethanol,
which decreased the Tm of both domains by 6 °C, while
DMSO had the least influence and decreased the Tm by
only 1.5 °C at 10%. Moreover, the apparent activity
decreased only marginally in the presence of cosol-
vents, and at comparable rates for all solvents used.
In order to investigate CYP505A30’s suitability as
a biocatalyst, we next looked at the enzyme’s ability to
perform reactions of value. One reason why P450-
BM3 gained high interest in the field of biocatalysis
was the successes in engineering the enzyme to accept
pharmaceutical compounds. In the absence of a crystal
structure, we first created a homology model of the
catalytic heme domain, using YASARA (Figure 2).
P450-BM3 was automatically chosen as the template
and despite the low sequence identity of 36%, the
model showed a good Z-score of   0.321. Notably, we
found a high degree of structural conservation in the
substrate access tunnel and especially the active site:
30 of 44 residues (68%) found in a vicinity of 10 Å
around P450 BM3’s Phe87, which is located centrally
in the tunnel, are identical. In order to investigate
whether this structural similarity would translate into
Figure 1. pH profile and solvent tolerance of CYP505A30. As the enzyme exhibits two distinct unfolding events, two Tm data sets
are plotted in (A) and (C). The higher stability curve can be assumed to correspond to the reductase domain, as it matches the
profile found when following the fluorescent flavin cofactor of this domain (Figure S3). pH profiles (A and B) were determined in
50 mM Na+ acetate, Na+ phosphate or Tris/HCl buffers, indicated in shades of grey. Solvent tolerance (C and D) was measured in
Tris/HCl at pH 7.4 in the presence of varying amounts of ethanol, methanol, acetonitrile and DMSO, indicated by various colors.
Activity measurements (B and D) were conducted in presence of 100 μM NADPH and 1 mM lauric acid.
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selectivity similarity, we created variants of
CYP505A30 based on P450-BM3 mutants described in
literature. We chose one of the first P450-BM3 mutants
reported to show activity on drug-like molecule – a
triple mutant targeting both the active site as well as its
access tunnel,[26] and a variant with two additional
mutations found by directed evolution, named M01 in
P450-BM3, which showed a further increased activity
towards several substrates.[27]
The mutations of the two variants, their position in
P450-BM3, and the homologous positions targeted in
CYP505A30 can be found in Table 1. One of the
residues is a phenylalanine located directly above the
heme (F87 in P450-BM3), which is assumed to be
critical for the acceptance of larger substrates. This
residue is conserved in both proteins, as is an active
site glutamate (BM3: E267, CYP505A30: E273)
whose exact role is still under debate.[5b] Two residues
are located at the tunnel entrance: P450-BM3’s
Leu188, whose hydrophobic nature is retained in
CYP505A30’s Ala194, and Arg47, corresponding to
the very different Gly53 in CYP505A30. The fifth
position, Gly415 (corresponding to Ala426 in
CYP505A30) has probably no influence on the activity
alterations found in P450-BM3-M01[27] and was only
added for a more realistic comparison. Wild-type
CYP505A30 and the triple and quintuple mutants were
then screened for activity on a panel of 21 active
pharmaceutical ingredients (APIs) using a previously
described whole cell conversion assay.[28] Control
reactions were performed with cells harboring the
same vector lacking the P450 gene. The compounds
and the conversion results are listed in Table 2.
Interestingly, we found that the mutations only
slightly affected the substrate scope of CYP505A30,
while they had a distinct effect on the product
distribution. All three variants oxidized eight com-
pounds, of which the two best substrates were
capsaicin and ibuprofen. Capsaicin is the pungency-
causing compound in chili peppers, and is undergoing
clinical trials as a therapeutic agent for various
diseases.[29] Ibuprofen is a synthetic, nonsteroidal anti-
inflammatory drug that finds widespread application as
an over-the-counter analgesic.[30] Structurally, the two
molecules show some similarity, as they are both
composed of an aromatic ring and an aliphatic chain
with a terminal isobutyl moiety (Table 2). Other
compounds that were converted by all variants were
the structurally diverse phenacetin, 2-naphthol, and
tolbutamide. Phenacetine as well as chlorzoxazone
were only converted in considerable amounts by the
wild type, while diclofenac was only accepted by the
mutants. For those cases, the reaction occurred
selectively and yielded only one product. Lidocaine
and piperine were converted in trace amounts by all
three variants. Capsaicin was most efficiently con-
verted by the wild-type enzyme, with 94.7% of the
starting material being turned over. By comparison of
the HPLC chromatograms with authentic standards
prepared and reported recently,[28b] the major product
could be identified as 8-hydroxycapsaicin, amounting
to 81% of the total products. The second most
abundant product (11%) resulted from epoxidation of
the double bond. Although producing similar relative
amounts of 8-hydroxycapsaicin, the M3x and M5x
mutants produced higher amounts of an unidentified
compound with identical mass to 8-hydroxycapsaicin,
likely the product of hydroxylation at another position.
The overall conversion yield was reduced to 73.6%
and 32.6%, respectively. A reduction of the conversion
yield from 43.1% to 10.4% was also observed for the
Figure 2. Access tunnel and active site of a homology model of
CYP505A30 (top panel), compared with P450-BM3 crystal
structure (PDB code 1FAG, bottom panel). The protein is
shown with blue (CYP505A30) or cyan (BM3) carbons as
sticks and the corresponding surfaces are cut open at various
planes (black). The heme cofactor is pink and the central iron
atom is violet.













Arg47 Gly53 Leu x x
Phe87 Phe93 Val x x
Leu188 Ala194 Asp x x
Glu267 Glu273 Val x
Gly415 Ala426 Ser x
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oxidation of ibuprofen by the M3x mutant, whereas the
M5x mutant still converted 37.5%. Furthermore, in
contrast to the wild type, which produced approx-
imately equal amounts of three different products, M5x
predominantly catalyzed the formation of one product
(77.3%).
To determine the structure of the three ibuprofen
metabolites, whole cell biooxidation was studied in a
200 mL preparative scale experiment using ibuprofen
Table 2. Conversion of APIs by CYP505A30.
[a] MW=Molecular weight.
[b] Products are depicted as percentages in various colors, unconverted substrate is depicted white. T= trace amounts converted.
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in a concentration of 3.75 mM (~150 mg). Several
samples were analyzed by HPLC/MS over a period of
9 hours and a final total conversion level of 35% was
achieved. Notably, 32% total conversion was already
reached after 3 hours. In agreement with analytical
scale experiments, ibuprofen was oxidized to 3
metabolites, to an extent of 11% (metabolite 1), 9%
(metabolite 2) and 15% (metabolite 3), respectively
(Figure 3). According to HPLC/MS, all three metabo-
lites had a mass of 221 gmol  1 (ESI, neg, SIM),
indicating mono-oxidation.[31] Cell emulsions were
extracted with ethyl acetate and the metabolites were
isolated by preparative reversed phase chromatogra-
phy. Isolated products (M1–M3) were analyzed via 1D
and 2D NMR spectroscopy and were confirmed to be
2-hydroxy-ibuprofen (M1), 3-hydroxy-ibuprofen (M2)
and 1-hydroxy-ibuprofen (M3) (Figures 3, S4–9).
These results are similar to biooxidations of ibuprofen
with CYP505X from Aspergillus fumigatus, another
homologue of P450-BM3.[28a] In line with its activity
on lauric acid,[19] CYP505A30 preferentially oxidizes
aliphatic side chains on (sub-)terminal positions; the
API screen demonstrates, however, that oxidation is
not restricted to such a structural element.
Conclusion
CYP505A30 could serve as a useful biocatalyst as it
combines attractive features for application: it is a self-
sufficient monooxygenase-reductase fusion enzyme
that is moderately thermostable, shows low suscepti-
bility to solvent exposure, and it can easily be
heterologously expressed in soluble form. The enzyme
shows a certain similarity to the well-established P450-
BM3, although the stability of the two enzyme
subdomains is inverted. CYP505A30’s more stable
reductase domain could therefore be used to generate a
P450-BM3 chimera with improved thermostability, as
has been demonstrated previously.[32] It’s broad pH-
tolerance could furthermore prove useful in mechanis-
tic or crystallographic studies. Its apparent high
tolerance to cosolvents is a particularly useful feature
for biooxidation of drugs, which are often large,
hydrophobic molecules with poor water solubility. The
basal activity on a surprisingly diverse range of
compounds already found for the wild-type advocates
CYP505A30’s use as a starting point for directed
evolution. Alternative enzymes are useful for early
screens, as enzyme engineering is much more success-
ful in expanding an initial (small) activity than
introducing one from scratch.[33] (Semi)random muta-
genesis and high-throughput activity screens to boost
activity proved highly successful for P450-BM3,[4,5b]
but our results suggest that a direct transfer of activities
may not be achieved by simply copying mutations. As
wild-type CYP505A30 already accepted several large
drug-like molecules, it is maybe less surprising that
our mutations had a smaller effect as anticipated. The
results nevertheless demonstrate that besides substrate




All standard reagents were purchased from Sigma Aldrich
unless otherwise stated.
Plasmid Generation
A synthetic and codon optimized gene of a NCBI genbank entry
XM_003663599 was ordered from GenScript (New Jersey,
USA). The gene was ordered to be cloned via HindIII and XhoI
in a pET28a vector with kanamycin resistance such that an N-
terminal 6x-Histidine tag was translationally fused to
CYP505A30. Plasmid integrity was confirmed by sequencing
(GATC-Biotech, Germany).
Mutagenesis
The triple and quintuple mutants were generated using the
multichange isothermal mutagenesis method.[34] Briefly, fully
complementary forward and reverse primers were designed at
the position that contained the mutation. PCR fragments from
one position to the next were then created by combining
forward and reverse primers of adjacent positions. The frag-
ments were then assembled by Gibson cloning,[35] using an in-
house prepared reaction mix. The assembled plasmid was
transformed, and a re-isolated plasmid from a single colony was
sent for sequencing to confirm the presence of the mutations.
Enzyme Expression and Purification
E. coli BL21 (DE3) competent cells were transformed with the
pET28a-6xHis-CYP505A30 vector (or the mutated version) and
the cells were plated on a Luria-Bertani (LB) agar plate
Figure 3. Preparative scale whole cell biooxidation of ibuprofen
by CYP505A30. Reaction volume: 200 mL; substrate concen-
tration: 3.75 mM. Conversion of ibuprofen gave three products
(M1-M3) according to HPLC/MS. The sum of M1 to M3
represents the overall total conversion yield. The three
monooxygenation products (221 gmol  1; ESI, neg, SIM) are 2-
hydroxy-ibuprofen (M1), 3-hydroxy-ibuprofen (M2) and 1-
hydroxy-ibuprofen (M3) according to NMR (Figures S4–9).
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containing 50 μg/mL kanamycin. A single colony was picked
and grown over night in LBKan. The overnight culture was used
to inoculate a main culture of terrific broth (TB) medium which
was shaken in an Erlenmayer flask without baffles at 37 °C until
an OD600 of approximately 1.8 was reached. Protein expression
was then induced by addition of 1 mM IPTG, upon which the
culture was shifted to 24 °C, where it was allowed to grow for
another 18 h. Cells were harvested by centrifugation and either
frozen at   20 °C or processed directly.
After resuspension in 50 mM Tris/HCl pH 7.4, cells were
sonicated for 15 minutes and cell debris was removed by
centrifugation. The cell free extract was loaded on a pre-
equilibrated gravity flow column containing appropriate
amounts of Ni2+ Sepharose HP (GEHealthcare). The column
was incubated at 4 °C rotating for 1 h and the flow through
discarded. The column was washed with 50 mM Tris/HCl
pH 7.4 and 50 mM Tris/HCl pH 7.4 containing 5 mM
imidazole. The protein was then eluted by washing the column
with 50 mM Tris/HCl pH 7.4 containing 500 mM imidazole.
Salt was removed by applying the solution to a pre-equilibrated
Econo-Pac 10DG desalting column (Bio-Rad). For storage,
10% glycerol was added, the protein shock-frozen in liquid
nitrogen and stored at   80 °C.
Spectra
CO-difference spectra were obtained by following the protocol
of Guengerich et al.[36] and recorded on a V-660 Jasco
spectrophotometer.
NADPH Consumption Assay
The reaction mix of 200 μL was buffered in 50 mM Tris/HCl
pH 7.4 and contained 1 μM purified P450, 1 mM of lauric acid
(except for the uncoupling measurement) and 100 μM NADPH
(or NADH in an initial experiment). The assays were performed
at room temperature. After addition of the cofactor, the mix was
transferred to a cuvette and the reaction followed at 340 nm on
a spectrophotometer (V-660 Jasco).
Bioconversion with Purified Enzyme and GC-MS
Analysis
The bioconversion mix of 1 mL with purified enzyme was
prepared in 50 mM Tris/HCl pH 7.4 and contained 1 μM
purified P450, 1 mM of lauric acid and 100 μM NADPH. For
cofactor regeneration, 1 μM purified thermostable phosphite
dehydrogenase[23] and 10 mM phosphite were added. The mix
was incubated at 30 °C in a closed 20 mL glass vial and mildly
agitated for 24 h. The reaction was stopped by adding NaCl
saturated 1 M HCl and subsequently equal amounts of ethyl
acetate were added. After thorough mixing and centrifugation,
the organic layer was removed and dried over anhydrous
magnesium sulfate. 1% TMS in BSTFA was added and the
sample incubated at 75 °C for 30 min. 1 μl was then injected in
a GC-MS QP2010 ultra instrument (Shimadzu) with electron
ionization and quadrupole separation, using an HP-1 column
(Agilent, 30 m×0.32 mm×0.25 μm). The settings of the GC
oven were 30 °C, wait 5 min, 5 °C/min ramp to 70, wait 5 min,
5 °C/min ramp to 130 °C, wait 5 min, 15 °C/min ramp to 325 °C,
wait 7 min.
Tm Determination using a Fluorescent Shift Assay
To determine the apparent melting temperature (Tm) in different
conditions, duplicate samples of 25 μl were prepared in a 96-
well thin-walled PCR plate. The samples contained 1 mg/mL
purified enzyme. The plate was heated from 20 °C to 90 °C,
increasing temperature by 0.5 °C every 10 seconds, using an
RT-PCR machine (CFX96-Touch, Bio-Rad Laboratories) that
measured fluorescence using a 450–490 excitation filter and a
515–530 nm emission filter. The melting point was defined as
the inflection point of the resulting melting curve, equivalent to
the maximum of the first derivative of the same curve.
Three different buffers at 50 mM concentration were used to
cover a wide pH range: sodium acetate for pH 3.6–5.6, sodium
phosphate for pH 5.8.–8.0, and Tris/HCl for pH 7.4–9.0.
Samples containing cosolvents were in 50 mM Tris/HCl pH 7.4.
Activity Assay in Varying Conditions
The same plate as for the Tm determination was prepared and
diluted in a 96-well microtiter plate with the same buffer layout
to achieve an enzyme concentration of 1 μM in each well.
Activity was measured in a plate reader (Synergy MX microtiter
plate reader, BioTek Instruments) with automatic dispensing of
NAPDH (final concentration 100 μM) and lauric acid as a
substrate (final concentration 1 mM) before measuring absorb-
ance at 340 nm for 1 min.
Whole Cell Conversions of APIs
Frozen cells were thawed and resuspended in potassium
phosphate buffer (100 mM pH 7.4, 8.5% w/v sucrose) in 24-
well plates. Trisodium citrate (50 μL, 1 M in ddH2O), NADP+
(50 μL, 1 mM in ddH2O), MgCl2 (10 μL, 1 M in ddH2O),
glucose (10 μL, 1 M in ddH2O), and GDH (5 μL, 10 mgmL-1
in ddH2O) were added to 825 μL of cell suspension. The
reaction was started by the addition of substrate (50 μL,
100 mM in DMSO). The final cell density at 600 nm (OD600)
was 100 in a total volume of 1 mL. The plate was sealed with
gas permeable adhesive seal and incubated at 30 °C and
120 rpm in an orbital shaker for 16 h. The reactions were
terminated by the addition of MeOH/ACN (1 mL 1:1 v/v). After
mixing, the reaction mix was centrifuged in a 1.5 mL Eppendorf
tube (5 min, 4 °C, 13,400 rpm). 200 μL of the supernatant were
analyzed in polypropylene microtiter plates by HPLC-MS on a
1200 HPLC Series equipped with G1379B degasser, G1312B
binary pump, SL G1367C HiP-ALS SL autosampler, G1314C
VWD SL UV detector, G1316B TCC SL column oven and
G1956B mass selective detector (MSD) with a Kinetex 50×
4.6 mm; 2.6u; C18; 100 An HPLC column (Phenomenex)
equipped with a UHPLC C18 Security Guard ULTRA cartridge
(Phenomenex).
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Scale up Reactions
CYP505A30 wild type was studied on preparative scale.
Preparative scale bioconversions were performed in baffled 2 L
Erlenmayer flasks in a total reaction volume of 200 mL (optical
density at 600 nm (OD600) corresponding to 100). 154 mg
ibuprofen (dissolved in 25 mL of DMSO) were used as the
substrate (3.75 mM). Ibuprofen biooxidation was monitored for
9 hours. Unreacted ibuprofen and its metabolites were extracted
with EtOAc. The solvent of the combined organic layers was
removed under reduced pressure. Ibuprofen was separated from
the metabolites by silica gel chromatography. Metabolite
compounds were separated via reverse phase HPLC on a
Thermo Scientific Dionex Ulti Mate 3000 Instrument using a
Macherey-Nagel VP 125/21 Nucleodur 100–5 C18 EC column.
A linear gradient of 2% to 65% MeCN in 24 min was used. 1D
and 2D NMR spectroscopy (1H, 13C, APT, COSY, HSQC,
HMBC) were recorded on a Bruker AVANCE III 300
spectrometer with autosampler (1H: 300.36 MHz; 13C:
75.53 MHz) and chemical shifts are referenced to residual
protonated solvent signals as internal standard. To facilitate the
interpretation, the C-spectra were proton decoupled to gain
better identification of the peaks.
Homology Model
The homology model of CYP505A30 was created using
YASARA version 15.11.18. The amino acid sequence in a
FASTA format was used as an input, and the program’s hm_
build.mcr macro was used with standard settings.[37] The model
was mainly built on the P450-BM3 structure with pdb code
1ZO9,[38] while some parts were the result of hybridization with
models built based on pdb codes 2IJ3, 3KX3, and 1ZO4. The
overall quality Z-score of the model was   0.321, which is
judged “good” by YASARA.
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